Skip to main content

TMDX

Stock
Health Care
Medical Devices

Performance overview

TMDX Price
Price Chart

Forward-looking statistics

Beta
1.59
Risk
72.74%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Company info

SectorHealth Care
IndustryMedical Devices
Employees375
Market cap$4.5B

Fundamentals

Enterprise value$4.7B
Revenue$488.2M
Revenue per employee
Profit margin10.03%
Debt to equity194.67

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$1.42
Dividend per share
Revenue per share$14.59
Avg trading volume (30 day)$91M
Avg trading volume (10 day)$84M
Put-call ratio

Macro factor sensitivity

Growth-1.6
Credit+4.3
Liquidity+1.1
Inflation-4.9
Commodities-0.3
Interest Rates-0.2

Valuation

Dividend yield0.00%
PEG Ratio78.30
Price to sales8.95
P/E Ratio78.30
Enterprise Value to Revenue9.71
Price to book16.41

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.

Zacks Investment Research (June 26, 2025)
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market

Scorpion Capital, on Friday, disclosed a short seller report on TransMedics Group Inc TMDX, accusing the organ transplant technology company of fraudulent practices, including kickbacks, billing fraud and unreported device failures.

Benzinga (January 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free